Remove Clinical Supply Remove Development Remove Gene Editing
article thumbnail

Logistics in Focus: Orchestrating the Challenges of Cell Therapy

Worldwide Clinical Trials

For example, once considered incurable and terminal, patients with sickle cell disease may reach new summits in their lives with gene editing technologies such as CRISPR to repair affected DNA and, in some cases, functionally cure the condition. There are also nuances for operational planning in cell therapy development programs.

article thumbnail

Oxford Biomedica and Beam Therapeutics sign CAR-T deal

The Pharma Data

. UK-based Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics for next-generation CAR-T therapeutics. The agreement also puts in place a three year clinical supply agreement for the two companies.